1. Home
  2. ENLV vs ELUT Comparison

ENLV vs ELUT Comparison

Compare ENLV & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$1.01

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$0.80

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENLV
ELUT
Founded
2005
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
23.3M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ENLV
ELUT
Price
$1.01
$0.80
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$13.00
$7.00
AVG Volume (30 Days)
495.3K
647.4K
Earning Date
03-30-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$21,746,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$0.66
$0.50
52 Week High
$2.10
$3.46

Technical Indicators

Market Signals
Indicator
ENLV
ELUT
Relative Strength Index (RSI) N/A 63.50
Support Level N/A $0.68
Resistance Level N/A $0.91
Average True Range (ATR) 0.00 0.09
MACD 0.00 0.03
Stochastic Oscillator 0.00 79.73

Price Performance

Historical Comparison
ENLV
ELUT

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: